Syndromes - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Syndromes

EDSA, NASDAQ

#Financial Data #Syndromes #Trending News

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023
16:30

EST

TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2023 and provided an update on its business. During the fiscal second quarter,

No Comments

NASDAQ, TSHA

#Corporate Presentation #Financial Data #Syndromes #Trending News #Upcoming Clinical Trial Presentation

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023
16:01

EST

Screening completed and dosing scheduled for first potential subject in the Phase 1/2 REVEAL trial in Rett syndrome; dosing of first adult patient with TSHA-102 expected in Q2 2023; initial available Phase 1/2 clinical data, primarily on safety, expected in Q2 2023 Clinical Trial Application (CTA) submission to United

No Comments

EGRX, NASDAQ

#Event #Syndromes

Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting

May 11, 2023
06:50

EST

WOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that two abstracts were accepted for presentation at the Society for Academic Emergency Medicine (SAEM) Annual Meeting, being held May 16-19, 2023, in Austin, Texas. “We are pleased to

No Comments

HRMY, NASDAQ

#Syndromes #Upcoming Presentation

HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING

May 10, 2023
08:05

EST

Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation PLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that new safety and

No Comments

NASDAQ, SONN

#Financial Data #Syndromes #Trending News

Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update

May 10, 2023
07:30

EST

Additional data presented from two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors. Cytokine data reveal extended PK profile for SON-1010: Induces prolonged and controlled IFNγ response No evidence of cytokine release syndrome Clinical benefit was seen in 36% of patients (5/14) with

No Comments

NASDAQ, SLNO

#Corporate Presentation #Featured #Financial Data #Syndromes #Trending News

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 9, 2023
16:05

EST

REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 and

No Comments

NASDAQ, STTK

#Financial Data #Syndromes #Trending News

Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023
16:00

EST

— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in June – — Dosed first patients in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab

No Comments

CPRX, NASDAQ

#Syndromes

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

May 9, 2023
08:03

EST

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality

No Comments

NASDAQ, QNRX

#Corporate Presentation #Featured #Financial Data #Syndromes #Trending News

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 8, 2023
17:00

EST

First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome Following successful public offering Quoin expects its cash runway will extend into 2H

No Comments

ANNX, NASDAQ

#Financial Data #Syndromes #Trending News

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

May 8, 2023
16:01

EST

Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data Anticipated from the Phase 1b Trial of ANX009 in Lupus Nephritis in 1H’23 Enrollment Expected to be Completed in Phase 3 Trial in Guillain-Barré Syndrome During 2H’23, with Initial

No Comments

< Page1 Page2 Page3 Page4 Page5 … Page66 >

Trending News

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

05/26/2023

SILVERCORP DECLARES SEMI-ANNUAL DIVIDEND OF US$0.0125 PER SHARE

05/26/2023

Halo Collective Provides Update on Status of Financial Statements

05/26/2023

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

05/26/2023

US Investors May Now Have Trading Access for Genius Group Shares on Upstream through US Broker Dealer

05/26/2023

Most read news

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn’s Disease

05/25/2023

Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.

05/24/2023

Avante Announces Private Placement Closing

05/24/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account